나노입자 제제 시장 : 제제화된 나노입자 유형별, 제제화된 유기 나노입자 유형별, 사업 규모별 및 지역별 - 동향과 예측(-2035년)

NANOPARTICLE FORMULATION MARKET: OVERVIEW

As per Roots Analysis, the global nanoparticle formulation market is estimated to grow from USD 6.8 billion in the current year to USD 15.2 billion by 2035, at a CAGR of 9.3% during the forecast period, till 2035.

Nanoparticle Formulation Market: Growth and Trends

Nanoparticles are engineered particles, typically measuring only a few billionths of a meter, that can be fabricated from lipids, polymers, metals and other compounds. Owing to their small size and tunable surface properties, they can move through the body more efficiently, interact closely with target cells and, in several cases, release an encapsulated drug in a controlled manner. Nanoparticle formulation refers to the process of packaging a therapeutic agent within or onto such particles so that it reaches the intended site of action, at the desired rate and in the desired concentration.

Drug developers are increasingly turning to nanoparticle-based formulations to overcome limitations associated with conventional dosage forms. A growing share of newer drug candidates suffers from poor aqueous solubility, rapid in vivo degradation or systemic toxicity when distributed indiscriminately across tissues. Nanoparticle-based delivery systems address these limitations by shielding the active ingredient, improving its solubility and enabling more precise delivery to diseased tissue, such as tumours. By enhancing drug stability, optimizing release kinetics and increasing local drug concentration at the target site, nanoparticle formulations can improve therapeutic efficacy while reducing off-target toxicity, often permitting lower effective doses and better preservation of healthy tissue.

Despite this progress, several unmet needs persist within the domain. Manufacturing nanoparticle formulations at commercial scale, while preserving batch-to-batch consistency, remains technically demanding and capital intensive. Regulatory guidelines specific to several newer nanotechnology platforms continue to evolve, creating uncertainty for developers, and the long-term in vivo behaviour of certain nanoparticle materials and designs is not yet completely understood. Smaller developers and companies based in emerging markets frequently lack access to the specialized expertise, equipment and testing infrastructure required to advance such candidates, which continues to slow the pace of development and commercialization across the industry.

The application scope of nanoparticle formulations is expanding well beyond infectious disease vaccines, with growing traction in oncology and gene therapy. Industry investment in this shift is already visible: Eli Lilly's proposed acquisition of Orna Therapeutics, valued at up to USD 2.4 billion, is intended to strengthen its in-vivo cell therapy platform built on circular RNA and lipid nanoparticles, underscoring the rising strategic importance of nanoparticle-enabled gene and cancer therapies to large pharmaceutical players.

Growth Drivers: Factors Propelling the Market Expansion

The nanoparticle formulation market is being propelled by the rising demand for innovative drug delivery systems across the pharmaceutical industry. Nanoparticles enable precise targeting and improved therapeutic outcomes, allowing for enhanced drug solubility, controlled release kinetics and the ability to bypass biological barriers, making them well suited to the delivery of poorly soluble drugs. This capability is proving particularly valuable in oncology, where targeted delivery helps minimize toxicity to healthy tissue.

Market growth is further supported by ongoing advancements in drug delivery technologies that continue to expand nanoparticle formulation capabilities. These improvements are enabling more precise control over particle size, surface properties and encapsulation efficiency, translating into better formulation performance overall. The integration of such advanced manufacturing techniques is reshaping nanoparticle development, improving both the precision and efficiency of production processes across the industry.

Market Challenges: Critical Barriers Hindering Progress

Scaling nanoparticle formulations from laboratory to commercial-scale production presents significant technical and operational hurdles. Formulations that show favourable pharmacokinetic and pharmacodynamic profiles at laboratory scale frequently require substantial re-optimization when transferred to pilot or manufacturing volumes, owing to altered momentum and mass transfer characteristics. Maintaining consistent product quality through this scale-up is both challenging and costly, requiring specialized equipment and stringent quality control systems.

The regulatory approval pathway for nanoparticle-based drugs and therapies adds a further layer of complexity, requiring extensive testing and validation to establish safety and efficacy. The absence of harmonized regulatory guidance for complex dosage forms built on novel excipients or delivery technologies can delay the approval of new products. Combined with substantial R&D costs, this regulatory uncertainty may discourage some pharmaceutical companies from committing capital to nanoparticle-based therapeutic programs.

Nanoparticle Formulation Market: Key Insights

The report delves into the current state of the nanoparticle formulation market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• More than 70 distinct technologies have been developed globally for the formulation of organic nanoparticles alone, reflecting a highly active and fragmented innovation landscape.
• Over 1,700 patents have been filed in the nanoparticle formulation domain, of which more than 50% have been filed in the US, underscoring the country's continued leadership in intellectual property generation within this space.
• The application scope of nanoparticle formulation technologies is broadening beyond infectious disease vaccines into oncology and gene therapy, supported by novel spleen-targeting lipid-mRNA complexes designed to enhance anti-tumour immune responses.
• Eli Lilly's proposed acquisition of Orna Therapeutics, for up to USD 2.4 billion, illustrates the growing strategic premium being placed on in-vivo cell therapy platforms built on circular RNA and lipid nanoparticle technology.
• CEPI's award of up to USD 9.7 million to POP Biotechnologies is advancing the SNAP nanoparticle vaccine platform toward Phase 1 trials, targeting rapid-response vaccines for epidemic threats such as H5N1 and Disease X.
• Advanced NanoTherapies raised over USD 31 million in a Series B round to advance its nanoparticle-enabled dual-drug balloon platform, signaling the extension of nanoparticle formulation expertise into cardiovascular and interventional applications.
• A dedicated nanoparticle evaluation framework, benchmarking organic, inorganic and carbon-based nanoparticles by clinical trial activity, patent-based innovation and research momentum, highlights where global competitive intensity is concentrated.
• Given the expanding technology and service-provider landscape, sustained patent activity and rising capital deployment across partnerships, licensing deals and financing rounds, the nanoparticle formulation market is well positioned for steady growth through 2035.

Nanoparticle Formulation Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Nanoparticle Formulated

• Organic Nanoparticles
• Inorganic Nanoparticles
• Carbon-based Nanoparticles

By Type of Organic Nanoparticle Formulated

• Polymeric Nanoparticles
• Lipid Nanoparticles
• Viral Nanoparticles
• Protein-based Nanoparticles
• Other Organic Nanoparticles

By Scale of Operation

• Preclinical
• Clinical
• Commercial

By Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America

Nanoparticle Formulation Market: Key Segmentation Insights

Organic Nanoparticles Lead the Market

Based on our market assessment, organic nanoparticles, including lipid-based nanoparticles, polymeric nanoparticles, micelles and dendrimers, currently holds the highest share of the nanoparticle formulation market. This leadership is attributed to their excellent biocompatibility, biodegradability and versatility in drug delivery applications. Additionally, this segment is expected to grow at a higher CAGR during the forecast period. This highest share is driven by the expanding development of targeted therapeutics, biologics, nucleic acid-based drugs and personalized medicines, alongside continued innovation in biodegradable and multifunctional delivery platforms.

Lipid Nanoparticles (LNPs) Dominate the Organic Nanoparticles Segment

According to our projections, lipid nanoparticles (LNPs) currently account for the largest share among organic nanoparticles, owing to their proven effectiveness in delivering a wide range of therapeutic agents, including nucleic acids, proteins, peptides and small-molecule drugs. Their strong biocompatibility, low toxicity and ability to protect sensitive payloads from degradation, combined with the successful commercialization of mRNA vaccines and therapeutics, have cemented their position as a preferred delivery platform. Polymeric nanoparticles are expected to grow at a significant pace over the forecast period, supported by their tunable physicochemical properties and ability to enable controlled, sustained drug release.

Commercial Scale Operations Hold the Largest Market Share

Based on our analysis, commercial-scale manufacturing currently accounts for the largest share of the nanoparticle formulation market. This highest share is driven by the increasing number of approved nanoparticle-based therapeutics and the corresponding need for robust, scalable and regulatory-compliant production processes. On the other hand, the clinical-scale segment is expected to grow at a higher CAGR during forecast period. This lucrative growth is fueled by the expanding pipeline of nanoparticle-based therapeutics under clinical evaluation in oncology, gene therapy, mRNA therapeutics and targeted drug delivery.

North America Dominates the Nanoparticle Formulation Market

According to our projections, North America holds the highest share and is expected to retain its position as the largest regional market for nanoparticle formulation. This dominance is supported by a highly developed pharmaceutical and biotechnology ecosystem, strong research infrastructure and substantial investment in nanomedicine and advanced drug delivery technologies. Further, the region is home to numerous leading pharmaceutical and biotechnology companies, academic research centers and contract development and manufacturing organizations (CDMOs) actively engaged in the development and commercialization of nanoparticle-based therapeutics.

Asia-Pacific Emerges as the Fastest-Growing Regional Market

The Asia-Pacific nanoparticle formulation market is anticipated to witness the highest CAGR during the forecast period. Growth is being fueled by increasing investment in pharmaceutical research and development, expanding biotechnology sectors and rising demand for advanced therapeutics. Countries such as China, India, Japan and South Korea are actively strengthening their nanotechnology and biopharmaceutical capabilities through government initiatives, infrastructure development and increased research funding, supported by the growing presence of regional biotechnology companies and rising outsourcing of formulation development to Asia-Pacific-based CDMOs.

Example Players In Nanoparticle Formulation Market

• Ascension Sciences
• DIANT Pharma
• ExonanoRNA
• Nanoform
• NanoVation Therapeutics
• NanoVelos
• NTT Biopharma
• Organoid-X BioTech
• Vaxinano

Expert Interview and Industry Insights

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Vice President of Analytical Sciences, Mid-sized Company, US
• Founder, Small Company, Denmark
• Co-founder, Director, Small Company, US
• Co-founder and Chief Executive Officer, Small Company; Chief Medical Officer, Mid-sized Company, US
• Chief Executive Officer, Consultant, Small Company, US
• Chief Executive Officer, Small Company, US
• Head of Early-stage Formulation Development & Process Design, Very Large Company, Germany
• Senior Director, Chemistry and Delivery Technologies, Mid-sized Company, US
• Scientific Director, Very Large Company, US
• Senior Scientist and Analytical Lead, Very Large Company, Germany
• Research Scientist, Very Large Company, Norway

NANOPARTICLE FORMULATION MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global nanoparticle formulation market, focusing on key market segments, including [A] type of nanoparticle formulated, [B] type of organic nanoparticle formulated, [C] scale of operation and [D] geographical regions.
• Technology Landscape: A detailed assessment of the overall nanoparticle formulation technology landscape, featuring information on several relevant parameters, such as type of nanoparticle(s) formulated, type of molecule(s) delivered, therapeutic area(s), compatible dosage form(s) and route(s) of administration. It also features detailed analysis of technology developers, based on parameters such as year of establishment, company size and location of headquarters.
• Service Providers Landscape: A detailed assessment of the overall nanoparticle formulation service providers landscape, featuring information on type of service provider, service(s) offered, scale of operation and application area(s), along with an analysis of service providers by year of establishment, company size and location of headquarters.
• Technology Competitiveness Analysis: A benchmarking analysis of nanoparticle formulation technologies offered by small, mid-sized and large players headquartered in North America, Europe, Asia-Pacific, MENA and the Rest of the World.
• Company Competitiveness Analysis: A benchmarking analysis of nanoparticle formulation service providers based in North America, Europe, Asia-Pacific and MENA.
• Company Profiles: In-depth profiles of prominent players engaged in offering nanoparticle formulation technologies and services, featuring information on their year of establishment, location of headquarters, company size, technology / service portfolio and recent developments and future outlook.
• Partnerships and Collaborations: An analysis of partnerships and collaborations inked in this domain since 2021, based on parameters such as year of partnership, type of partnership, type of partner and geography, including intercontinental, intracontinental, local and international deals.
• Patent Analysis: An analysis of patents filed / granted related to nanoparticle formulation, based on several relevant parameters, such as type of patent, publication year, geography, CPC symbols, type of applicant, patent benchmarking and patent valuation.
• Nanoparticle Evaluation Framework: A proprietary benchmarking analysis of organic, inorganic and carbon-based nanoparticles, based on number of clinical trials, extent of innovation, trends in research activity and current global competition.
• Case Study: Technology Licensing Deals: A review of recent nanoparticle formulation technology licensing deals, including an analysis of the financial components involved in such agreements.
• Executive Insights: First-hand perspectives captured through interview transcripts with senior stakeholders across analytical sciences, formulation development and executive leadership functions.

Key Questions Answered in this Report

• Which are the leading companies in the nanoparticle formulation market?
• Which region dominates the nanoparticle formulation market?
• What are the key trends observed in the nanoparticle formulation market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by nanoparticle formulation developers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences and behaviour of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

• Complementary PPT Insights Pack
• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. BACKGROUND

• 1.1. Context
• 1.2. Project Objectives

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Project Commencement
  • 2.3.2. Data Collection
  • 2.3.3. Data Validation
  • 2.3.4. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Introduction to Nanoparticles
• 6.3. Classification of Nanoparticles
  • 6.3.1. Organic Nanoparticles
  • 6.3.2. Inorganic Nanoparticles
  • 6.3.3. Carbon-based Nanoparticles
• 6.4. Methods of Nanoparticle Formulation
• 6.5. Applications of Nanoparticle-based Systems
• 6.6. Challenges associated with Nanoparticle Formulation
• 6.7. Need for Outsourcing Nanoparticle Formulation
• 6.8. Concluding Remarks

7. TECHNOLOGY LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Nanoparticle Formulation: Technology Landscape
  • 7.2.1. Analysis by Type of Nanoparticle(s) Formulated
  • 7.2.2. Analysis by Type of Organic Nanoparticle(s) Formulated
  • 7.2.3. Analysis by Type of Inorganic Nanoparticle(s) Formulated
  • 7.2.4. Analysis by Type of Molecule(s) Delivered
  • 7.2.5. Analysis by Therapeutic Area(s)
  • 7.2.6. Analysis by Compatible Dosage Form(s)
  • 7.2.7. Analysis by Route(s) of Administration
• 7.3. Nanoparticle Formulation: Technology Developer Landscape
  • 7.3.1. Analysis by Year of Establishment
  • 7.3.2. Analysis by Company Size
  • 7.3.3. Analysis by Location of Headquarters
  • 7.3.4. Analysis by Company Size and Location of Headquarters
  • 7.3.5. Most Active Players: Analysis by Number of Technologies

8. SERVICE PROVIDERS LANDSCAPE

• 8.1. Chapter Overview
• 8.2. Nanoparticle Formulation: Service Providers Landscape
  • 8.2.1. Analysis by Year of Establishment
  • 8.2.2. Analysis by Company Size
  • 8.2.3. Analysis by Location of Headquarters
  • 8.2.4. Analysis by Company Size and Location of Headquarters
  • 8.2.5. Analysis by Location of Facilities
  • 8.2.6. Analysis by Type of Service Provider(s)
  • 8.2.7. Analysis by Type of Nanoparticle(s) Formulated
    • 8.2.7.1. Analysis by Type of Organic Nanoparticle(s) Formulated
    • 8.2.7.2. Analysis by Type of Inorganic Nanoparticle(s) Formulated
  • 8.2.8. Analysis by Type of Service Provider(s) and Type of Nanoparticle(s) Formulated
  • 8.2.9. Analysis by Service(s) Offered
  • 8.2.10. Analysis by Company Size and Service(s) Offered
  • 8.2.11. Analysis by Scale of Operation
  • 8.2.12. Analysis by Application Area(s)

9. TECHNOLOGY COMPETITIVENESS ANALYSIS

• 9.1. Chapter Overview
• 9.2. Assumptions / Key Parameters
• 9.3. Methodology
• 9.4. Technology Competitiveness Analysis
  • 9.4.1. Nanoparticle Formulation Technologies Offered by Players based in North America
    • 9.4.1.1. Nanoparticle Formulation Technologies Offered by Small Players based in North America
    • 9.4.1.2. Nanoparticle Formulation Technologies Offered by Mid-sized and Large Players based in North America
  • 9.4.2. Nanoparticle Formulation Technologies Offered by Players based in Europe
  • 9.4.3. Nanoparticle Formulation Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Rest of the World

10. COMPANY COMPETITIVENESS ANALYSIS

• 10.1. Chapter Overview
• 10.2. Assumptions / Key Parameters
• 10.3. Methodology
• 10.4. Company Competitiveness Analysis
  • 10.4.1. Nanoparticle Formulation Service Providers based in North America
  • 10.4.2. Nanoparticle Formulation Service Providers based in Europe
  • 10.4.3. Nanoparticle Formulation Service Providers based in Asia-Pacific and Middle East and North Africa

11. COMPANY PROFILES

• 11.1. Chapter Overview
• 11.2. Ascension Sciences
  • 11.2.1. Company Overview
  • 11.2.2. Technology Portfolio
  • 11.2.3. Service Portfolio
  • 11.2.4. Recent Developments and Future Outlook
• 11.3. DIANT Pharma
• 11.4. ExonanoRNA
• 11.5. Nanoform
• 11.6. NanoVation Therapeutics
• 11.7. NanoVelos
• 11.8. NTT Biopharma
• 11.9. Organoid-X BioTech
• 11.10. Vaxinano

12. PARTNERSHIPS AND COLLABORATIONS

• 12.1. Chapter Overview
• 12.2. Partnership Models
• 12.3. Nanoparticle Formulation Technologies and Services: Partnerships and Collaborations
  • 12.3.1. Analysis by Year of Partnership
  • 12.3.2. Analysis by Type of Partnership
  • 12.3.3. Analysis by Year and Type of Partnership
  • 12.3.4. Analysis by Type of Partner
  • 12.3.5. Analysis by Location of Headquarters of Partner
  • 12.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
  • 12.3.7. Most Active Players: Analysis by Number of Partnerships
  • 12.3.8. Analysis by Geography
    • 12.3.8.1. Intercontinental and Intracontinental Deals
    • 12.3.8.2. Local and International Deals

13. PATENT ANALYSIS

• 13.1. Chapter Overview
• 13.2. Scope and Methodology
• 13.3. Nanoparticle Formulation Domain: Patent Analysis
  • 13.3.1. Analysis by Publication Year
  • 13.3.2. Analysis by Type of Patent and Publication Year
  • 13.3.3. Analysis by Geography
  • 13.3.4. Analysis by CPC Symbols
  • 13.3.5. Analysis by Type of Organization
  • 13.3.6. Leading Industry Players: Analysis by Number of Patents
• 13.4. Patent Benchmark Analysis
  • 13.4.1. Analysis by Patent Characteristics
• 13.5. Patent Valuation Analysis

14. NANOPARTICLE EVALUATION FRAMEWORK

• 14.1. Chapter Overview
• 14.2. Key Assumptions and Methodology
• 14.3. Organic Nanoparticles
  • 14.3.1. Number of Clinical Trials
  • 14.3.2. Extent of Innovation
  • 14.3.3. Trends in Research Activity
  • 14.3.4. Current Global Competition
  • 14.3.5. Nanoparticle Evaluation Framework: Organic Nanoparticles
• 14.4. Inorganic Nanoparticles
  • 14.4.1. Number of Clinical Trials
  • 14.4.2. Extent of Innovation
  • 14.4.3. Trends in Research Activity
  • 14.4.4. Current Global Competition
  • 14.4.5. Nanoparticle Evaluation Framework: Inorganic Nanoparticles
• 14.5. Carbon-based Nanoparticles
  • 14.5.1. Number of Clinical Trials
  • 14.5.2. Extent of Innovation
  • 14.5.3. Trends in Research Activity
  • 14.5.4. Current Global Competition
  • 14.5.5. Nanoparticle Evaluation Framework: Carbon-based Nanoparticles
  • 14.5.6. Nanoparticle Evaluation Framework: Concluding Remarks

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 15.1. Chapter Overview
• 15.2. Key Assumptions and Forecast Methodology
• 15.3. Global Nanoparticle Formulation Services Market, till 2035
• 15.4. Nanoparticle Formulation Services Market: Analysis by Type of Nanoparticle Formulated
  • 15.4.1. Nanoparticle Formulation Services Market: Analysis by Type of Organic Nanoparticle Formulated
    • 15.4.1.1. Nanoparticle Formulation Services Market for Polymeric Nanoparticles, till 2035
    • 15.4.1.2. Nanoparticle Formulation Services Market for Lipid Nanoparticles, till 2035
    • 15.4.1.3. Nanoparticle Formulation Services Market for Viral Nanoparticles, till 2035
    • 15.4.1.4. Nanoparticle Formulation Services Market for Protein-based Nanoparticles, till 2035
    • 15.4.1.5. Nanoparticle Formulation Services Market for Other Organic Nanoparticles, till 2035
  • 15.4.2. Nanoparticle Formulation Services Market: Analysis by Inorganic Nanoparticle Formulated
  • 15.4.3. Nanoparticle Formulation Services Market: Analysis by Carbon-based Nanoparticle Formulated
• 15.5. Nanoparticle Formulation Services Market: Analysis by Scale of Operation
  • 15.5.1. Nanoparticle Formulation Services Market for Preclinical Operations, till 2035
  • 15.5.2. Nanoparticle Formulation Services Market for Clinical Operations, till 2035
  • 15.5.3. Nanoparticle Formulation Services Market for Commercial Operations, till 2035
• 15.6. Nanoparticle Formulation Services Market: Analysis by Key Geographical Regions
  • 15.6.1. Nanoparticle Formulation Services Market in North America, till 2035
  • 15.6.2. Nanoparticle Formulation Services Market in Europe, till 2035
  • 15.6.3. Nanoparticle Formulation Services Market in Asia-Pacific, till 2035
  • 15.6.4. Nanoparticle Formulation Services Market in Middle East and North Africa, till 2035
  • 15.6.5. Nanoparticle Formulation Services Market in Latin America, till 2035

16. CASE STUDY: TECHNOLOGY LICENSING DEALS

• 16.1. Chapter Overview
• 16.2. Recent Technology Licensing Deals
• 16.3. Concluding Remarks

17. CONCLUSION

18. EXECUTIVE INSIGHTS

19. APPENDIX 1: TABULATED DATA